Paxlovid and molnupiravir were approved in Aotearoa early in 2022 for treating COVID-19 in adults at increased risk of progressing to severe disease, hospitalisation or death. Variations in the dispensing of these medicines suggest inequitable access. Read this microlearning to find out more.
Education
The hub for all your learning resources.
Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.